Open AccessInhaled antiseptics and inhaled antiviral non-prescription drugs in the prevention of ARVI, in particular COVID-19: an epidemiological study
Author(s) -
Y. I. Feshchenko,
Mykola Gumeniuk,
Mykola Lynnyk,
O. Ya. Dziublyk,
Mykhailo Kuzhko,
О. V. Теreshkovych,
O.V. Khmel,
І.О. Panashchuk,
M.V. Yashchenko,
Oleksii Denysov,
Т.А. Sprynsian
Publication year - 2021
Publication title -
infusion and chemotherapy
Language(s) - English
Resource type - Journals
eISSN - 2709-0957
pISSN - 2663-0338
DOI - 10.32902/2663-0338-2021-4-5-15
Subject(s) - medicine , covid-19 , epidemiology , inhalation , medical prescription , drug , disease , pharmacology , infectious disease (medical specialty) , anesthesia
BACKGROUND. The article presents the results of a continuous, cross-sectional, non-interventional, multicenter retrospective epidemiological study, which included cases of 3443 participants. Questionnaires and rapid test for antibodies to SARS-CoV-2 were used to collect data.
OBJECTIVE. To determine the relationship between the systematic use of additional drugs for the prevention of COVID-19, including inhaled antiseptics and inhaled antiviral drugs, separately and in combination with other drugs, and the risk of developing of coronavirus disease (COVID-19).
RESULTS AND DISCUSSION. 396 participants (11.8 %) took inhaled antiseptics in any period since March 2020, and 410 participants (12.2 %) took inhaled antivirals. A statistically significant protective relationship between episode of COVID-19 when taking inhaled antiseptics and inhaled antiviral drugs (risk ratio 0.901; 95 % confidence interval 0.856-0.948) was determined.
CONCLUSIONS. The use of inhaled antiseptics and inhaled antiviral drugs as additional methods of prevention of COVID-19 has shown a statistically significant effect not only on reducing the risk of COVID-19, but different combinations of inhaled antiseptics or inhaled antiviral drugs with other drug groups as additional methods of preventing COVID-19 had a statistically significant protective relationship with the episode of the disease, with the severity of COVID-19 and with the need for hospitalization.